Effect of thymosin-α(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B.

Jiang YF, Ma ZH, Zhao PW, Pan Y, Liu YY, Feng JY, Niu JQ

The Journal of international medical research1 Jan 2010Cited by 13 (Europe PMC)

PMID21227010DOI10.1177/147323001003800620PepBankPUB-21227010

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In HBeAg-positive chronic hepatitis B, thymosin alpha‑1 increased the proportions of Th1 cytokine-producing cells compared with baseline and healthy controls.
In plain wordsIn people with HBeAg-positive chronic hepatitis B, thymosin alpha‑1 raised the share of Th1 immune cells making cytokines compared with baseline and healthy controls.
Peptide
Thymosin alpha-1
Outcome
IncreaseTh1 cytokine-producing T cells (IL-2, IFN-gamma, TNF-alpha)
Study
n = 25
Comparator
Baseline and healthy controls
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg or 3.2 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
In all patients treated with TA(1), cytokine levels and the proportion of peripheral blood mononuclear cells producing these cytokines were significantly increased, compared with baseline and healthy controls.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated the immune response after TA(1) monotherapy in 25 HBV e antigen (HBeAg)-positive patients randomized to receive either 1.6 mg active TA(1) (group A), 1.6 mg recombinant TA(1) (group B) or 3.2 mg recombinant TA(1) (group C) monotherapy for 52 weeks.
Report a problemFND-2122701001
02HumanRandomized controlled trialEfficacy outcome
In HBeAg-positive chronic hepatitis B, thymosin alpha‑1 increased the proportion of IL-4-producing Th2 cells compared with baseline and healthy controls.
In plain wordsIn people with HBeAg-positive chronic hepatitis B, thymosin alpha‑1 raised the share of Th2 immune cells making IL-4 compared with baseline and healthy controls.
Peptide
Thymosin alpha-1
Outcome
IncreaseTh2 cytokine-producing T cells (IL-4)
Study
n = 25
Comparator
Baseline and healthy controls
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg or 3.2 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
In all patients treated with TA(1), cytokine levels and the proportion of peripheral blood mononuclear cells producing these cytokines were significantly increased, compared with baseline and healthy controls.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated the immune response after TA(1) monotherapy in 25 HBV e antigen (HBeAg)-positive patients randomized to receive either 1.6 mg active TA(1) (group A), 1.6 mg recombinant TA(1) (group B) or 3.2 mg recombinant TA(1) (group C) monotherapy for 52 weeks.
Report a problemFND-2122701002
03HumanRandomized controlled trialEfficacy outcome
In HBeAg-positive chronic hepatitis B, the proportion of IFN-gamma-producing cells under thymosin alpha‑1 rose over time to higher levels than in healthy controls.
In plain wordsIn people with HBeAg-positive chronic hepatitis B, thymosin alpha‑1 raised IFN-gamma-producing cells above the level of healthy controls.
Peptide
Thymosin alpha-1
Outcome
IncreaseIFN-gamma-producing cells versus healthy controls
Study
n = 25
Comparator
Healthy controls
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg or 3.2 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
The proportions of each cytokine-producing cell increased gradually over time and were restored to normal levels, and proportions of IFN-γ and IL-4-producing cells reached higher levels than in normal (healthy) controls.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated the immune response after TA(1) monotherapy in 25 HBV e antigen (HBeAg)-positive patients randomized to receive either 1.6 mg active TA(1) (group A), 1.6 mg recombinant TA(1) (group B) or 3.2 mg recombinant TA(1) (group C) monotherapy for 52 weeks.
Report a problemFND-2122701003
04HumanRandomized controlled trialEfficacy outcome
In HBeAg-positive chronic hepatitis B, the proportion of IL-4-producing cells under thymosin alpha‑1 rose over time to higher levels than in healthy controls.
In plain wordsIn people with HBeAg-positive chronic hepatitis B, thymosin alpha‑1 raised IL-4-producing cells above the level of healthy controls.
Peptide
Thymosin alpha-1
Outcome
IncreaseIL-4-producing cells versus healthy controls
Study
n = 25
Comparator
Healthy controls
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg or 3.2 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
The proportions of each cytokine-producing cell increased gradually over time and were restored to normal levels, and proportions of IFN-γ and IL-4-producing cells reached higher levels than in normal (healthy) controls.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated the immune response after TA(1) monotherapy in 25 HBV e antigen (HBeAg)-positive patients randomized to receive either 1.6 mg active TA(1) (group A), 1.6 mg recombinant TA(1) (group B) or 3.2 mg recombinant TA(1) (group C) monotherapy for 52 weeks.
Report a problemFND-2122701004
05HumanRandomized controlled trialEfficacy outcome
In HBeAg-positive chronic hepatitis B, the higher dose of thymosin alpha‑1 showed better efficacy against HBV than the other regimens studied.
In plain wordsIn people with HBeAg-positive chronic hepatitis B, the higher dose of thymosin alpha‑1 worked better against the virus than the other doses studied.
Peptide
Thymosin alpha-1
Outcome
IncreaseEfficacy against HBV, higher dose versus other doses
Study
n = 25
Comparator
Other thymosin alpha-1 regimens studied
Outcome group
Antiviral activity · Infection
Studied dose
3.2 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
higher-dose TA(1) exhibited better efficacy against HBV, compared with other treatments studied.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated the immune response after TA(1) monotherapy in 25 HBV e antigen (HBeAg)-positive patients randomized to receive either 1.6 mg active TA(1) (group A), 1.6 mg recombinant TA(1) (group B) or 3.2 mg recombinant TA(1) (group C) monotherapy for 52 weeks.
Report a problemFND-2122701005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1/2NCT02646189

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Replicor Inc.n = 12Aug 2011 to Aug 2013

Hepatitis B, Chronic

Trial page ClinicalTrials.govUpdated 5 Jan 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC